Cargando…
Recent Advancements of Treatment for Leptomeningeal Carcinomatosis
Treatment of Leptomeningeal carcinomatosis (LMC) from solid cancers has not advanced noticeably since the introduction of intra-cerebrospinal fluid (CSF) chemotherapy in the 1970's. The marginal survival benefit and difficulty of intrathecal chemotherapy injection has hindered its wide spread u...
Autores principales: | Gwak, Ho-Shin, Lee, Sang Hyun, Park, Weon Seo, Shin, Sang Hoon, Yoo, Heon, Lee, Seung Hoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Neurosurgical Society
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534733/ https://www.ncbi.nlm.nih.gov/pubmed/26279806 http://dx.doi.org/10.3340/jkns.2015.58.1.1 |
Ejemplares similares
-
Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis
por: Kim, Hye Seon, et al.
Publicado: (2019) -
Cerebrospinal fluid metabolomic profiles can discriminate patients with leptomeningeal carcinomatosis from patients at high risk for leptomeningeal metastasis
por: Yoo, Byong Chul, et al.
Publicado: (2017) -
Cerebrospinal Fluid Profiles and Their Changes after Intraventricular Chemotherapy as Prognostic or Predictive Markers for Patients with Leptomeningeal Carcinomatosis
por: Kwon, Ji-Woong, et al.
Publicado: (2021) -
Efficacy of Slow Rate Ventriculolumbar Perfusion Chemotherapy for Leptomeningeal Carcinomatosis: Interim Result of a Phase II Study
por: Choi, Young Hoon, et al.
Publicado: (2019) -
Retrospective Analysis of Cerebrospinal Fluid Profiles in 228 Patients with Leptomeningeal Carcinomatosis : Differences According to the Sampling Site, Symptoms, and Systemic Factors
por: Shim, Youngbo, et al.
Publicado: (2016)